Our results on EDNRA overexpression and its correlation with poor survival indicate remarkable potential for developing selective EDNRA antagonists as potential target therapies for gastric cancer, especially for patients with confirmed high expression level of EDNRA, who might benefit from personalised treatments. The gene discussed is EDNRA; the disease is gastric cancer.